Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, open-label phase 3 study to investigate the efficacy and safety of aldoxorubicin compared to investigator's choice in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who either relapsed or were refractory to prior non-adjuvant chemotherapy

Next Previous
X
Search
Trial Profile

A multicenter, randomized, open-label phase 3 study to investigate the efficacy and safety of aldoxorubicin compared to investigator's choice in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who either relapsed or were refractory to prior non-adjuvant chemotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldoxorubicin (Primary) ; Dacarbazine; Docetaxel; Doxorubicin; Gemcitabine; Ifosfamide; Pazopanib
  • Indications Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors CytRx Corporation; ImmunityBio; LadRx Corporation

    • Most Recent Events

    • 07 Jun 2018 Results presented in the CytRx Corporation media release.
    • 07 Jun 2018 According to a CytRx Corporation media release, pooled data from this and other study (700249151) were presented at the American Society of Clinical Oncology 2018 Annual Meeting.
    • 16 Feb 2018 This trial has been Discontinued in Italy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top